Previous 10 | Next 10 |
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities Vitual fireside chat with members of Compugen's management team will take place on June 8 at 12:00 PM ET PR Newswire HOLON, Israel , June 1, 2021 /PRNewswire/ --...
Gainers: [[CHMA]] +5.7%. [[STIM]] +5.2%. [[TMDX]] +3.3%. [[SELB]] +3.2%. [[CGEN]] +2.8%.Losers: [[WMG]] -12.8%. [[QMCO]] -4.8%. [[OKTA]] -4.2%. [[NXGN]] -3.9%. [[LIZI]] -3.8%. For further details see: CHMA, STIM, WMG and NXGN among after-hours movers
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q1 2021 Earnings Call May 13, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Compugen Ltd. (CGEN) Q1 2021 Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2021 Earnings Conference Call May 13, 2021 08:30 AM ET Company Participants Anat Cohen-Dayag - CEO Ari Krashin - CFO and COO Henry Adewoye - Chief Medical Officer Conference Call Participants Mark Breidenbach - Oppenheimer Stephen Willey - Stifel Daina Graybosch - SVB ...
Shares of Compugen (NASDAQ: CGEN) were jumping 7.9% as of 11:03 a.m. EDT on Thursday. The solid gain came after the drugmaker provided its first-quarter update before the market opened. Today's solid uptick for the biotech stock likely had little to do with Compugen's Q1 fin...
Compugen (NASDAQ:CGEN) is scheduled to announce Q1 earnings results on Thursday, May 13th, before market open.The consensus EPS Estimate is -$0.13 For further details see: Compugen Q1 Earnings Preview
Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series PR Newswire HOLON, Israel , May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive targ...
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen Research to explore the underlying biology and mechanism of action of the novel myeloid target for cancer immunotherapy PR Newswire ...
Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021 PR Newswire HOLON, Israel , May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discove...
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting PR Newswire HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy co...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...